One of the biggest patent cliffs is set to hit the pharmaceutical industry this decade, with major players bracing for a blow ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the 25 stocks Jim Cramer recently shared insights on. While discussing drug ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

Global Sepsis Treatment Market Report: Growth, Expansion, and Strategic Insights (2025–2033) The Global Sepsis Treat ...

The SPDR Russell 1000 Yield Focus ETF (ONEY) made its debut on 12/02/2015, and is a smart beta exchange traded fund that ...

It will grow to $2.12 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%.” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, July 4, 2025 /EINPresswire.com/ -- Save ...

Gynecologic clear cell cancers are aggressive malignant neoplasms with low response rates to chemotherapy. Among patients ...

AstraZeneca Plc is discussing a partnership deal with Summit Therapeutics Inc. in which it could pay as much as $15 billion ...

Bristol Myers Squibb Co. annual cash flow and in depth look at BMY operating, investing, and financing activities.

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...

The global cancer monoclonal antibodies (mAbs) market , valued at $55.6 billion in 2021, is projected to reach $106.8 billion by 2031, growing at a CAGR of 7% from 2022 to 2031. This exponential ...